Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abcellera Biologics Inc (NQ: ABCL )

2.610 -0.010 (-0.38%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,753,204
Open 2.670
Bid (Size) 2.590 (20)
Ask (Size) 2.710 (3)
Prev. Close 2.620
Today's Range 2.580 - 2.670
52wk Range 2.400 - 6.055
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD
The AI-powered drug discovery process is expected to grow by a 30% CAGR between now and 2030 which should result in approximately 50 novel therapies and generate annual sales in excess of $50 billion... 
Via Talk Markets
AbCellera Biologics (ABCL) Q2 2024 Earnings Call Transcript
ABCL earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial

Performance

YTD
-54.45%
-54.45%
1 Month
-22.55%
-22.55%
3 Month
-28.30%
-28.30%
6 Month
-51.12%
-51.12%
1 Year
-52.55%
-52.55%

More News

Read More
AbCellera Reports Q2 2024 Business Results
From AbCellera Biologics Inc.
Via Business Wire
AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines
From AbCellera Biologics Inc.
Via Business Wire
AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD
Via Talk Markets
"Bubble" In AI/Semiconductor Stocks Began To Re-Inflate On Friday
Via Talk Markets
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
Via The Motley Fool
AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD
Via Talk Markets
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
Via Talk Markets
3 Biotech Stocks That Can Gain Exponentially By Leveraging AI
Via Talk Markets
AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024
From AbCellera Biologics Inc.
Via Business Wire
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
Via Talk Markets
AI-Focused Drug Discovery Stocks Portfolio Down 4% W/e June 14th
Via Talk Markets
Down 57%, Is AbCellera Biologics a Buy on the Dip?
Via The Motley Fool
AI-Focused Drug Discovery Stocks Portfolio Down 2% In May; Up 4% Last Week
Via Talk Markets
AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
From AbCellera Biologics Inc.
Via Business Wire
Largest Clinical-Stage BioTech Drug Stocks Declined Slightly Last Week
Via Talk Markets
A $50B AI Drug Discovery Revolution Has Begun - Here Are 6 Stocks To Consider Investing In
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week
Via Talk Markets
3 Stock Gems Hiding in the Nasdaq
Via InvestorPlace
5 Of 7 AI Categories Rose, Slightly,Over Past Week
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
AbCellera Biologics (ABCL) Q1 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
ABCL Stock Earnings: AbCellera Biologics Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
AbCellera Reports Q1 2024 Business Results
From AbCellera Biologics Inc.
Via Business Wire
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.